Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00706446 · ClinicalTrials.gov registry record · NA
The Effects of Different Long-acting Bronchodilator Medications on Asthma Patients With Different Genetic Variations
A NA study, sponsored by Brigham and Women's Hospital.
- Terminated
- Registry status
- NA
- Development phase
- 255
- Enrollment target
NCT00706446 is a NA study that was terminated before completion, run by Brigham and Women's Hospital. The registered enrollment target is 255 participants.
The verdict
NCT00706446, a NA study, was terminated before completion, sponsored by Brigham and Women's Hospital.
- TERMINATED
- Registry status
- NA
- Development phase
- 255 participants
- Enrollment target
Study Summary
This study is looking at the effects of certain long-acting bronchodilators on patients with asthma who have specific genetic variations. The investigators are interested in a certain common genetic variation in the receptor for beta-agonists, which is found in as many of one-sixth of the population. There is evidence that patients with asthma who have this variation may not do as well when treated with albuterol on a regular basis. The investigators will be looking at whether patients with this variation have more asthma exacerbations over the course of a year when treated with salmeterol or formoterol, which are long-acting forms of albuterol; and whether these patients have fewer exacerbations when treated with tiotropium, which is a different long-acting bronchodilator that does not act at this receptor. In both groups patients will also be receiving inhaled steroids.
Interventions
- DRUG Salmeterol
- DRUG Formoterol
- DRUG Fluticasone propionate
- DRUG tiotropium bromide
- DRUG budesonide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 255 participants |
| Start Date | 2008-06 |
| Est. Completion | 2011-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00706446
The ClinicalTrials.gov registry entry for NCT00706446 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 255 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Salmeterol is the first listed.
NCT00706446 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00706446 about?
NCT00706446 is a clinical study titled "The Effects of Different Long-acting Bronchodilator Medications on Asthma Patients With Different Genetic Variations". This study is looking at the effects of certain long-acting bronchodilators on patients with asthma who have specific genetic variations. The investigators are interested in a certain common genetic variation in the receptor for beta-agonists, which is found in as many of one-sixth of the population...
What is the current status of trial NCT00706446?
This trial is currently terminated. It is a NA study. The enrollment target is 255 participants. The study started on 2008-06. Estimated completion is 2011-09.
What interventions are being tested in trial NCT00706446?
The interventions under investigation include: Salmeterol (DRUG), Formoterol (DRUG), Fluticasone propionate (DRUG), tiotropium bromide (DRUG), budesonide (DRUG).
Who is sponsoring clinical trial NCT00706446?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.